Orchard Therapeutics' Strimvelis for the vanishingly rare "bubble boy" disease adenosine deaminase deficiency (ADA-SCID) – originally developed by GlaxoSmithKline – reached the market in 2016 ...
Behçet's disease (BD) is a multisystem inflammatory disorder currently classified as a vasculitis. Its etiopathogenesis is unclear, but environmental, genetic and autoimmune factors have been ...
The London-based company is developing the gene therapy for adenosine deaminase severe combined immunodeficiency, commonly known as ADA-SCID or “bubble baby” disease. OTL-101 is similar to GSK ...
It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and ...
It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and ...
The raw sequencing data were initially processed through splicing, filtering, and de-chimerization using deficiency of adenosine deaminase 2 DADA2 version 1.26.0 (Callahan et al., 2016) with default ...
Antinuclear antibody was detected in 16.9% of cases assessed, and adenosine deaminase (ADA) was elevated in 10.7%. Serologic tests for syphilis and human T-lymphotrophic virus type 1 antibody were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback